Specialized Testing
Hepatitis Testing Interpretive Data
This page provides you with the interpretive data for the following Hepatitis assays.
Hepatitis A Antibody (HAV), IgM |
Order Name:HEP A M AB Test Number: 3603500 |
|
| Reactive | Non-Reactive (NR) | Equivocal |
|---|---|---|
| Recent onset of hepatitis A infection. | No evidence of recent hepatitis A infection. | Indicates that test should be repeated in 1-2 weeks. |
| Test Notes | ||
| It should be noted that the assay performance characteristics of the IgM anti-HAV assay have not been established for immunocompromised or immunosuppressed patients or on cord blood, neonatal specimens, infants or children less than 12 years age. | ||
Hepatitis B Core IgM Antibody |
Order Name:HEP BCOR M Test Number: 5553650 |
|
| Reactive | Non-Reactive (NR) | Equivocal |
|---|---|---|
| Recent onset of hepatitis B infection. | No evidence of recent hepatitis B infection. | Indicates that test should be repeated in 1-2 weeks. |
| Test Notes | ||
| It should be noted that the assay performance characteristics of the IgM anti-HEP B core assay have not been established for either immunocompromised, immunosuppressed patients or on cord blood, neonatal specimens, infants or children less than 12 years age. | ||
Hepatitis B Surface Antibody, IgG |
Order Name:HEP AB BS Test Number: 3611850 |
|
| Test Description | ||
|---|---|---|
|
The reported index results are traceable to the World Health Organization (WHO) Hepatitis B Immunoglobulin 1st International Reference Preparation. An Index value of 1.00 is equivalent to 10mIU/mL of HBsAb. The CDC guidelines indicate that an accepted criteria for immunity to HBV is HBsAb activity of >/= 10mIU/mL (MMWR1990:39 (RR-2):1-26) or an index value of >/= 1.00. The system reports the HBsAb antibody activity as reactive or non-reactive along with the Index value. |
||
| Reactive | Non-Reactive (NR) | |
| >/= 1.00 Index Value or >/= 10 mIU/mL; Have Protective Immunity | < 1.00 Index Value or < 10 mIU/mL; Does Not Have Protective Immunity) | |
| Test Notes | ||
| It should be noted that the assay performance characteristics of the HBsAb assay has not been established for either immunocompromised, immunosuppressed patients or on cord blood specimens from neonates, infants, or children less than 12 years age. | ||
Hepatitis B Surface Antigen |
Order Name:HEP AG BS Test Number: 3603000 |
|
| Reactive | Non-Reactive (NR) | |
|---|---|---|
| Recent onset of hepatitis B infection. | No evidence of recent hepatitis B infection. | |
| Test Notes | ||
| It should be noted that the assay performance characteristics of the Hepatitis B Surface Antigen assay have not been established for either immunocompromised, immunosuppressed patients or on cord blood, neonatal sepecimens, infants, or children less than 12 years age. | ||
Hepatitis C Antibody (HCV Ab) |
Order Name:HEP C AB Test Number: 5590850 |
|
| Test Description | ||
|---|---|---|
|
HCV INDEX: In order to improve the reliability of reported HCV Ab test results the manufacturer has established that all indexes > 1.0 are considered positive. However, the manufacturer's recommendation of the indexes reported can be interpreted in the light of the confirmatory strip immunoblot (RIBA) as follows: |
||
| Index Valur | Percent Confirmed Positive: | |
| 1.00 - 3.99 | 25% | |
| 4.00 - 7.99 | 77% | |
| 8.00 - 10.99 | 73% | |
| > 11.00 | 99.9% | |
| Test Notes | ||
| Positive results with an index of > 11.0 are accepted by CDC as having anti-HCV status with no need of confirmation. However, it is recommended that any index between 1.0 and 10.99 be further evaluated to determine if the response is due to the early stages of sero- conversion, declining antibody activity due to a resolved HCV infection, weak response due to either immunosuppression, immunodeficiency or a false positive. Suggested further testing for patients with an index between 1.0 and 10.99 is to either evaluate for the presence of virus by utilizing the HCV PCR Quantitative test, requiring a fresh specimen, and/or re-evaluate for a comparable antibody response in 6-8 weeks. A RIBA test is generally not helpful in a majority of the weak responses. Serum is the specimen of choice. It should be noted that the assay performance characteristics of the anti-HCV Ab assay have not been established for the immunocompromised or immunosuppressed patients or on cord blood or specimens from neonates, infants or children less than 12 years age. | ||